FindTrial
Sign In

A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523479-49-00
Enrollment
18
Registered
2026-06-22
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colitis ulcerative

Brief summary

Percentage of Participants Achieving Clinical Remission Per Modified Mayo Score (MMS) at Week 12

Detailed description

Percentage of Participants With One or More Adverse Events (AEs), Percentage of Participants Who Discontinued Study Intervention Due to an AE, Percentage of Participants Achieving Clinical Response Per MMS at Week 12, Percentage of Participants With Endoscopic Improvement at Week 12, Percentage of Participants Achieving Clinical Remission Per Partial Modified Mayo Score (pMMS) at Week 12, Percentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement at Week 12

Interventions

DRUGMK-8690
DRUGPlacebo for MK-8690

Sponsors

Merck Sharp & Dohme LLC
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Percentage of Participants Achieving Clinical Remission Per Modified Mayo Score (MMS) at Week 12—

Secondary

MeasureTime frame
Percentage of Participants With One or More Adverse Events (AEs), Percentage of Participants Who Discontinued Study Intervention Due to an AE, Percentage of Participants Achieving Clinical Response Per MMS at Week 12, Percentage of Participants With Endoscopic Improvement at Week 12, Percentage of Participants Achieving Clinical Remission Per Partial Modified Mayo Score (pMMS) at Week 12, Percentage of Participants Achieving Histologic-Endoscopic Mucosal Improvement at Week 12—

Outcome results

None listed

Source: EU CTIS · Data processed: Jun 24, 2026